Company |
Company |
Value (M) |
Type/Product Area |
Terms/Details |
Date |
AUGUST | |||||
Apeiron Biologics AG (Vienna) |
Rentschler Biotechnologie GmbH (Laupheim, Germany) |
ND |
Partnership to manufacture GMP material for APN311, a chimeric antibody in development for neurobloastoma |
The manufacturing process will be transferred to Rentschler |
8/2/13 |
Romark Laboratories Inc. (Tampa, Fla.) |
Lupin Ltd. (Mumai, India) |
ND |
Licensing agreement granting Lupin exclusive rights to promote, distribute and market Alinia for oral suspension in the U.S. market |
Alinia is used to treat diarrhea caused by cryptosporidium and giardia |
8/8/13 |
SEPTEMBER | |||||
Cardiome Pharma Corp. (Vancouver, British Columbia) |
Lifepharma (Z.A.M.) Ltd. (Nicosia, Cyprus) |
ND |
Agreement to sell and distribute atrial fibrillation drug Brinavess exclusively in Cyprus |
Terms were not disclosed |
9/25/13 |
Pozen Inc. (Chapel Hill, N.C.) |
Sanofi US (division of Sanofi SA; Paris) |
$35 |
License agreement for the commercialization of Pozen’s coordinated-delivery tablets combining immediate-release omeprazole, a proton pump inhibitor, and enteric-coated aspirin in a single tablet |
Sanofi will have exclusive rights to commercialize all combinations in the U.S.; Pozen gets an up-front payment of $15M, pre-commercial milestone payments of up to $20M, plus other milestone payments and royalties |
9/6/13 |
OCTOBER | |||||
Allergan Inc. (Irvine, Calif.) |
Medytox Inc. (Seoul, South Korea) |
$362 |
Worldwide licensing agreement, excluding South Korea, to commercialize neurotoxin candidates currently in development, including a liquid-injectable product |
Medytox was to receive $65M up front, up to $116.5M in milestone payments, plus $180.5M in commercial milestone payments and royalties, for a total deal value of $362M |
10/7/13 |
Auxilium Pharmaceuticals Inc. (Chesterbrook, Pa.) |
Vivus Inc. (Mountain View, Calif.) |
$300 |
Deal to market the erectile dysfunction drug Stendra in the U.S. and Canada |
Auxilium will pay Vivus a one-time license fee of $30M and a $15M regulatory milestone if the FDA approves the Stendra label to reflect an onset of action of 15 minutes or less, as well as $255M in sales milestones – making the deal worth $300M, plus royalties on sales |
10/14/13 |
Cardiome Pharma Corp. (Vancouver, British Columbia) |
Biospifar SA (Bogota, Colombia) |
ND |
Agreement to sell and distribute Brinavess exclusively in Colombia |
Biospifar agreed to specific annual commercial goals for the atrial fibrillation drug |
10/10/13 |
Catalyst Biosciences Inc. (South San Francisco) |
Isu Abxis (Korea) |
ND |
Collaboration to develop Catalyst’s next-generation Factor IX development candidate, FIX-NG, for the prevention and treatment of bleeding in hemophilia B |
The firms will share in profits on the development and commercialization of FIX-NG worldwide, and Isu will pay an up-front licensing fee and milestones through Phase I |
10/10/13 |
Qrxpharma Ltd. (Sydney) |
Aspen Pharmacare Holdings Ltd. (Durban, South Africa) |
A$0.25 ($0.24) |
Licensing agreement for rights to commercialize immediate-release Moxduo in South Africa |
Qrxpharma is set to receive a milestone payment of $237,800 upon regulatory approval of immediate-release Moxduo in South Africa, plus double-digit royalties; Qrxpharma retained rights to the intravenous and controlled release formulations of Moxduo |
10/16/13 |
Swedish Orphan Biovitrum AB (Stockholm) |
Hyperion Therapeutics Inc. (South San Francisco) |
ND |
Exclusive rights to distribute Ravicti oral liquid on a named-patient basis for the chronic treatment of urea cycle disorders in the Middle East |
Sobi will be able to provide Ravicti in Saudi Arabia, Oman, United Arab Emirates, Jordan, Kuwait, Qatar and Bahrain |
10/2/13 |
|
Notes: The date indicated refers to the BioWorld Today issue in which the news item can be found. | |||||